Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Results of exenatide myocardial protection in revascularization study

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 9, 2013, Pages 2252-2260

  Woo, Jong Shin ^a   Kim, Weon ^a   Ha, Sang Jin ^a   Kim, Jin Bae ^a   Kim, Soo Joong ^a   Kim, Woo Shik ^a   Seon, Hyun Ju ^b   Kim, Kwon Sam ^a  

^a Kyung Hee University College of Medicine   (South Korea)

^b Chonnam National University Medical School   (South Korea)

Author keywords

exenatide; magnetic resonance imaging; myocardial infarction; percutaneous coronary intervention; reperfusion injury

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SODIUM CHLORIDE; SULFONYLUREA; TROPONIN I;

ADULT; AGED; ANOREXIA; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; DYSPNEA; FEMALE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARAMETERS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

EXENATIDE; MAGNETIC RESONANCE IMAGING; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION INJURY;

AGED; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; CHI-SQUARE DISTRIBUTION; CREATINE KINASE, MB FORM; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIUM; PEPTIDES; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; TROPONIN I; VENOMS; VENTRICULAR FUNCTION, LEFT;

EID: 84883295202     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301586     Document Type: Article

References (22)

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409-1439. (Pubitemid 350041474)
2. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962-965. (Pubitemid 38282847)
3. Fields AV, Patterson B, Karnik AA, Shannon RP. Glucagon-like peptide-1 and myocardial protection: more than glycemic control. Clin Cardiol. 2009;32:236-243.
4. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009;53:501-510.
5. Read PA, Hoole SP, White PA, Khan FZ, O'Sullivan M, West NE, Dutka DP. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc Interv. 2011;4:266-272.
6. Lønborg J, Vejlstrup N, Kelbæk H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:1491-1499.
7. Ha SJ, Kim W, Woo JS, Kim JB, Kim SJ, Kim WS, Kim MK, Cheng XW, Kim KS. Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels. Arterioscler Thromb Vasc Biol. 2012;32:474-480.
8. Lønborg J, Kelbæk H, Vejlstrup N, Bøtker HE, Kim WY, Holmvang L, Jørgensen E, Helqvist S, Saunamäki K, Terkelsen CJ, Schoos MM, Køber L, Clemmensen P, Treiman M, Engstrøm T. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv. 2012;5:288-295.
9. Cho GY, Marwick TH, Kim HS, Kim MK, Hong KS, Oh DJ. Global 2-dimensional strain as a new prognosticator in patients with heart failure. J Am Coll Cardiol. 2009;54:618-624.
10. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, Aupetit JF, Bonnefoy E, Finet G, André-Fouët X, Ovize M. Postconditioning the human heart. Circulation. 2005;112:2143-2148. (Pubitemid 41475808)
11. Woo JS, Kim WS, Yu TK, Ha SJ, Kim SY, Bae JH, Kim KS. Prognostic value of serial global longitudinal strain measured by two-dimensional speckle tracking echocardiography in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2011;108:340-347.
12. Remmelink M, Sjauw KD, Henriques JP, Vis MM, van der Schaaf RJ, Koch KT, Tijssen JG, de Winter RJ, Piek JJ, Baan J Jr. Acute left ventricular dynamic effects of primary percutaneous coronary intervention from occlusion to reperfusion. J Am Coll Cardiol. 2009;53:1498-1502.
13. Møller JE, Pellikka PA, Hillis GS, Oh JK. Prognostic importance of diastolic function and filling pressure in patients with acute myocardial infarction. Circulation. 2006;114:438-444. (Pubitemid 44264826)
14. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, Shannon RP. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006;317:1106-1113. (Pubitemid 43764114)
15. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121-1135.
16. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagonlike peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005;54:146-151. (Pubitemid 40105106)
17. Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail. 2008;1:153-160.
18. Norris SL, Lee N, Thakurta S, Chan BK. Exenatide efficacy and safety: a systematic review. Diabet Med. 2009;26:837-846.
19. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res. 2006;70:240-253.
20. Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol. 2004;44:1103-1110. (Pubitemid 39165147)
21. Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol. 1994;266(3 Pt 2):H1145-H1152. (Pubitemid 24121336)
22. Bernink FJ, Timmers L, Diamant M, Scholte M, Beek AM, Kamp O, Marques KM, Denham RN, Chen WJ, Doevendans PA, van Rossum AC, van Royen N, Horrevoets AJ, Appelman Y. Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: The EXAMI study. Int J Cardiol. 2013;167:289-290. doi:10.1016/j.ijcard.2012.09.204.